Unknown

Dataset Information

0

Cycling Quiescence in Temozolomide Resistant Glioblastoma Cells Is Partly Explained by microRNA-93 and -193-Mediated Decrease of Cyclin D.


ABSTRACT: Glioblastoma multiforme (GBM) is a fatal malignancy of the central nervous system, commonly associated with chemoresistance. The alkylating agent Temozolomide (TMZ) is the front-line chemotherapeutic agent and has undergone intense studies on resistance. These studies reported on mismatch repair gene upregulation, ABC-targeted drug efflux, and cell cycle alterations. The mechanism by which TMZ induces cell cycle arrest has not been well-established. TMZ-resistant GBM cells have been linked to microRNA (miRNA) and exosomes. A cell cycle miRNA array identified distinct miRNAs only in exosomes from TMZ-resistant GBM cell lines and primary spheres. We narrowed the miRs to miR-93 and -193 and showed in computational analyses that they could target Cyclin D1. Since Cyclin D1 is a major regulator of cell cycle progression, we performed cause-effect studies and showed a blunting effects of miR-93 and -193 in Cyclin D1 expression. These two miRs also decreased cell cycling quiescence and induced resistance to TMZ. Taken together, our data provide a mechanism by which GBM cells can exhibit TMZ-induced resistance through miRNA targeting of Cyclin D1. The data provide a number of therapeutic approaches to reverse chemoresistance at the miRNA, exosomal and cell cycle points.

SUBMITTER: Munoz JL 

PROVIDER: S-EPMC6395452 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cycling Quiescence in Temozolomide Resistant Glioblastoma Cells Is Partly Explained by microRNA-93 and -193-Mediated Decrease of Cyclin D.

Munoz Jessian L JL   Walker Nykia D ND   Mareedu Satvik S   Pamarthi Sri Harika SH   Sinha Garima G   Greco Steven J SJ   Rameshwar Pranela P  

Frontiers in pharmacology 20190222


Glioblastoma multiforme (GBM) is a fatal malignancy of the central nervous system, commonly associated with chemoresistance. The alkylating agent Temozolomide (TMZ) is the front-line chemotherapeutic agent and has undergone intense studies on resistance. These studies reported on mismatch repair gene upregulation, ABC-targeted drug efflux, and cell cycle alterations. The mechanism by which TMZ induces cell cycle arrest has not been well-established. TMZ-resistant GBM cells have been linked to mi  ...[more]

Similar Datasets

| S-EPMC3973225 | biostudies-literature
| S-EPMC6466611 | biostudies-literature
| S-EPMC6395391 | biostudies-literature
| S-EPMC3144254 | biostudies-literature
| S-EPMC1899986 | biostudies-literature
| S-EPMC7252967 | biostudies-literature
2023-05-17 | PXD042080 | Pride
| S-EPMC5537714 | biostudies-literature
| S-EPMC10762356 | biostudies-literature
| S-EPMC7282490 | biostudies-literature